Double-Blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder

被引：0
|
作者：
Arif Khan
Anjana Bose
George S. Alexopoulos
Carl Gommoll
Dayong Li
Chetan Gandhi
机构：
[1] Northwest Clinical Research Center,Department of Psychiatry and Behavioral Sciences
[2] Duke University School of Medicine,undefined
[3] Forest Research Institute,undefined
[4] Weill Medical College of Cornell University,undefined
来源：
Clinical Drug Investigation | 2007年 / 27卷
关键词：
Major Depressive Disorder; Duloxetine; Escitalopram; Last Observation Carry Forward; MADRS Total Score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and objective: Escitalopram is the most selective serotonin reuptake inhibitor antidepressant; in contrast, duloxetine inhibits both serotonin and norepinephrine reuptake. Double-blind comparison studies may help guide treatment decisions by revealing the relative benefits of different therapeutic approaches. This study evaluated the efficacy and safety of escitalopram versus duloxetine in the acute treatment of patients with moderate to severe major depressive disorder.
引用
收藏
页码：481 / 492
页数：11
相关论文
共 50 条
  • [1] Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder
    Khan, Arif
    Bose, Anjana
    Alexopoulos, George S.
    Gommoll, Carl
    Li, Dayong
    Gandhi, Chetan
    [J]. CLINICAL DRUG INVESTIGATION, 2007, 27 (07) : 481 - 492
  • [2] Double-blind comparison of escitallopram and duloxetine in the acute treatment of major depressive disorder
    Jonas, Jeffrey
    Bose, Anjana
    Alexopoulos, George S.
    Gommoll, Carl
    Li, Dayong
    Gandhi, Chetan
    [J]. NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S166 - S166
  • [3] Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder
    Bielski, R
    Ventura, D
    Chang, C
    Korotzer, A
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S263 - S263
  • [4] A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder
    Bielski, RJ
    Ventura, D
    Chang, CC
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (09) : 1190 - 1196
  • [5] A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder
    Perahia, David G. S.
    Pritchett, Yili Lu
    Kajdasz, Daniel K.
    Bauer, Michael
    Jain, Rakesh
    Russell, James M.
    Walker, Daniel J.
    Spencer, Kimberly A.
    Froud, Debbie M.
    Raskin, Joel
    Thase, Michael E.
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 2008, 42 (01) : 22 - 34
  • [6] Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial
    Goldstein, DJ
    Mallinckrodt, C
    Lu, YL
    Demitrack, MA
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (03) : 225 - 231
  • [7] Comparative efficacy of escitalopram and duloxetine in the acute treatment of major depressive disorder
    Bose, A.
    Gommoll, C.
    Li, D.
    Gandhi, C.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S349 - S350
  • [8] Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence
    Muhonen, Leea H.
    Loennqvist, Jouko
    Juva, Kati
    Alho, Hannu
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (03) : 392 - 399
  • [9] Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder
    Pigott, Teresa A.
    Prakash, Apurva
    Arnold, Lesley M.
    Aaronson, Scott T.
    Mallinckrodt, Craig H.
    Wohlreich, Madelaine M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1303 - 1318
  • [10] A pharmacoeconomic comparison of escitalopram and duloxetine in treatment of major depressive disorder (MDD) in the United Kingdom
    Wade, A. G.
    Fernandez, J. L.
    Francois, C.
    Hansen, K.
    Despiegel, N.
    Danchenko, N.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A306 - A306
12345